FDA approves azelastine eye drops unit dose

FDA approves azelastine eye drops unit dose

The U.S. Food and Drug Administration (FDA) has approved Meda's registration
application for azelastine eye drops in unit dose (Optivar Unit Dose). The
substance azelastine is an antihistamine and the eye drop formulation is
approved for treatment of allergic conjunctivitis in adults and pediatrics.

Meda is conducting a broad development program for the azelastine substance,
both as azelastine eye drops and azelastine nasal spray. Azelastine eye drops
sample is one part of that development program.

For more information, please contact:

Anders Larnholt, Investor Relations, tel. +46 8 630 19 62, +46 709 458 878
email: anders.larnholt@meda.se

MEDA AB (publ) is an international specialty pharma company that concentrates on
marketing and market-adapted product development. Acquisitions and long-term
partnerships are fundamental factors that drive the company's strategy. Meda is
represented with own organisations in 26 countries and with more than 1 500
employees within marketing and sales. Meda's products are sold in approximately
120 countries world-wide. The Meda share is listed under Large Cap on the OMX
Nordic Stock Exchange. Find out more, visit www.meda.se.